DRAPER, Utah , Nov. 08, 2023 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its third quarter of fiscal 2024 financial results following the close of regular stock market trading hours on Tuesday, December 5, 2023. Following the news release, HealthEquity management plans to host a conference call for investors on Tuesday, December 5, 2023, at 4:30 p.m. ET during which management will review the Company’s third quarter results.
HealthEquity Third Quarter Fiscal Year 2024 Results Conference Call
| Date: | December 5, 2023 |
| Time: | 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time |
| Dial-In: | 1-833-630-1956 (US and Canada) 1-412-317-1837 (International) |
| Conference ID: | HealthEquity, Inc. call |
| Webcast: | ir.healthequity.com |
A replay of the conference call will be made available on the Company’s website at ir.healthequity.com.
About HealthEquity
HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for our 15 million benefit accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Investor Relations Contact:
Richard Putnam
801-727-1000
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$82.49 |
| Daily Change: | -0.54 -0.65 |
| Daily Volume: | 629,225 |
| Market Cap: | US$7.150B |
March 18, 2025 February 18, 2025 January 13, 2025 November 12, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
